Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Anti-interleukin-2 receptor antibodies for the prevention of rejection in liver transplant recipients: a systematic review and meta-analysis.

Zhang Y, Jin W, Cai X.

Ann Med. 2017 Feb 21:1-12. doi: 10.1080/07853890.2016.1257862. [Epub ahead of print]

PMID:
27813419
2.

Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.

Jones-Hughes T, Snowsill T, Haasova M, Coelho H, Crathorne L, Cooper C, Mujica-Mota R, Peters J, Varley-Campbell J, Huxley N, Moore J, Allwood M, Lowe J, Hyde C, Hoyle M, Bond M, Anderson R.

Health Technol Assess. 2016 Aug;20(62):1-594. doi: 10.3310/hta20620.

3.

Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation.

Haasova M, Snowsill T, Jones-Hughes T, Crathorne L, Cooper C, Varley-Campbell J, Mujica-Mota R, Coelho H, Huxley N, Lowe J, Dudley J, Marks S, Hyde C, Bond M, Anderson R.

Health Technol Assess. 2016 Aug;20(61):1-324. doi: 10.3310/hta20610.

4.

Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Immune Therapy.

Singh RK, Humlicek T, Jeewa A, Fester K.

Pediatr Crit Care Med. 2016 Mar;17(3 Suppl 1):S69-76. doi: 10.1097/PCC.0000000000000626. Review.

PMID:
26945331
5.

Efficacy and Safety of Basiliximab Versus Daclizumab in Kidney Transplantation: A Meta-Analysis.

Sun ZJ, Du X, Su LL, Zhang XD, Wang W.

Transplant Proc. 2015 Oct;47(8):2439-45. doi: 10.1016/j.transproceed.2015.08.009.

PMID:
26518947
6.

Immunosuppressants for the prophylaxis of corneal graft rejection after penetrating keratoplasty.

Abudou M, Wu T, Evans JR, Chen X.

Cochrane Database Syst Rev. 2015 Aug 27;(8):CD007603. doi: 10.1002/14651858.CD007603.pub2. Review.

PMID:
26313245
7.

Cost Effectiveness of Monoclonal Antibody Therapy for Rare Diseases: A Systematic Review.

Park T, Griggs SK, Suh DC.

BioDrugs. 2015 Aug;29(4):259-74. doi: 10.1007/s40259-015-0135-4. Review.

PMID:
26263903
8.

Belatacept for kidney transplant recipients.

Masson P, Henderson L, Chapman JR, Craig JC, Webster AC.

Cochrane Database Syst Rev. 2014 Nov 24;(11):CD010699. doi: 10.1002/14651858.CD010699.pub2. Review.

PMID:
25416857
9.

Impact of induction immunosuppression on survival in heart transplant recipients: a contemporary analysis of agents.

Whitson BA, Kilic A, Lehman A, Wehr A, Hasan A, Haas G, Hayes D Jr, Sai-Sudhakar CB, Higgins RS.

Clin Transplant. 2015 Jan;29(1):9-17. doi: 10.1111/ctr.12469. Epub 2014 Dec 12.

PMID:
25284138
10.

Interleukin-2 receptor antagonists for pediatric liver transplant recipients: a systematic review and meta-analysis of controlled studies.

Crins ND, Röver C, Goralczyk AD, Friede T.

Pediatr Transplant. 2014 Dec;18(8):839-50. doi: 10.1111/petr.12362. Epub 2014 Oct 4. Review.

PMID:
25283839
11.

Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients.

Penninga L, Wettergren A, Wilson CH, Chan AW, Steinbrüchel DA, Gluud C.

Cochrane Database Syst Rev. 2014 Jun 5;(6):CD010253. doi: 10.1002/14651858.CD010253.pub2. Review.

PMID:
24901467
12.

Antibody induction versus corticosteroid induction for liver transplant recipients.

Penninga L, Wettergren A, Wilson CH, Chan AW, Steinbrüchel DA, Gluud C.

Cochrane Database Syst Rev. 2014 May 31;(5):CD010252. doi: 10.1002/14651858.CD010252.pub2. Review.

PMID:
24880007
13.

Immunosuppressive T-cell antibody induction for heart transplant recipients.

Penninga L, Møller CH, Gustafsson F, Gluud C, Steinbrüchel DA.

Cochrane Database Syst Rev. 2013 Dec 2;(12):CD008842. doi: 10.1002/14651858.CD008842.pub2. Review.

PMID:
24297433
14.

Antibody induction therapy for lung transplant recipients.

Penninga L, Møller CH, Penninga EI, Iversen M, Gluud C, Steinbrüchel DA.

Cochrane Database Syst Rev. 2013 Nov 27;(11):CD008927. doi: 10.1002/14651858.CD008927.pub2. Review.

PMID:
24282128
15.

A contemporary analysis of induction immunosuppression in pediatric lung transplant recipients.

Hayes D Jr, Kirkby S, Wehr AM, Lehman AM, McConnell PI, Galantowicz M, Higgins RS, Whitson BA.

Transpl Int. 2014 Feb;27(2):211-8. doi: 10.1111/tri.12240. Epub 2013 Dec 16.

16.

Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis.

Morgan RD, O'Callaghan JM, Knight SR, Morris PJ.

Transplantation. 2012 Jun 27;93(12):1179-88. doi: 10.1097/TP.0b013e318257ad41. Review.

PMID:
22660659
17.

Belatacept: a new biologic and its role in kidney transplantation.

Su VC, Harrison J, Rogers C, Ensom MH.

Ann Pharmacother. 2012 Jan;46(1):57-67. doi: 10.1345/aph.1Q537. Epub 2012 Jan 3. Review.

PMID:
22215686
18.

Belatacept: from rational design to clinical application.

Wekerle T, Grinyó JM.

Transpl Int. 2012 Feb;25(2):139-50. doi: 10.1111/j.1432-2277.2011.01386.x. Epub 2011 Dec 7. Review.

19.

[Immunosuppression for living donor renal allograft recipients].

Pascual Santos J, Hernández Marrero D.

Nefrologia. 2010;30 Suppl 2:80-4. doi: 10.3265/Nefrologia.pre2010.Nov.10694. Spanish.

20.

Interleukin-2 receptor antagonists in liver transplantation: a meta-analysis of randomized trials.

Wang XF, Li JD, Peng Y, Dai Y, Shi G, Xu W.

Transplant Proc. 2010 Dec;42(10):4567-72. doi: 10.1016/j.transproceed.2010.09.169.

PMID:
21168739

Supplemental Content

Loading ...
Support Center